Seminario impartido por Silvia Lucia Cuffini, del Instituto de Ciência e Tecnologia. (ICT), Universidade Federal de São Paulo (UNIFESP). Brasil.
The majority of active pharmaceutical ingredients (APIs) for different therapies are used in the solid-state form. Therefore, the knowledge and control of their physical properties is relevant for design the formulation, quality control, therapeutic action, regulatory aspects and new patents. Crystalline materials have specific physicochemical properties depending the molecular arrangement in the solid forms. The intra and intermolecular interactions and their packaging determine relevant properties for pharmaceutical applications such as: solubility, dissolution rate, solid-state stability, etc. Thus, not only the academic research but also the pharmaceutical industries were interested in the solid state and crystal structure modifications studies, as a strategy in order to improve the solid state properties of APIs, new regulations and patents etc. In this work, different solid state studies of drugs of our research group will be presented related to: polymorphic quantification studies of suspension forms of Mebendazole, correlation between microstructure and bioequivalence essas (HIV/ AIDS antiretroviral: Efavirenz) and rational design of multicomponents (co-crystals and eutectics) of APIs for treatment of diseases such as: HIV / AIDS antiretrovirals :Nevirapine). (1) CRYSTAL GROWTH & DESIGN, v. 20, p. 688-698, 2020. (2) CRYST.ENG.COMM. 22, p. 7460-7474, 2020. (3) EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, v. 91, p. 52-58, 2015. (4) CRYSTAL GROWTH & DESIGN, v. 15, p. 5233-5239, 2015. (5) INTERNATIONAL JOURNAL OF PHARMACEUTICS Volume 650, 25 January 2024, 123721. (6) JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS Volume 242, 15 May 2024, 116038.
Fecha del seminario: 27/06/2024 12:00
Lugar del seminario: sala 215
Ponente del seminario: Silvia Lucia Cuffini
